bendamustine hydrochloride has been researched along with Cancer, Second Primary in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dote, S; Goto, R; Inose, R; Kobayashi, Y; Muraki, Y | 1 |
| Butera, JN; Castillo, JJ; Olszewski, AJ; Reagan, JL | 1 |
| Andersen, MA; da Cunha-Bang, C; Frederiksen, H; Grønbaek, K; Hjalgrim, H; Niemann, CU; Rostgaard, K; Rotbain, EC | 1 |
| Bar, MH; Bartlett, NL; Cabanillas, F; Chen, Z; Cheson, BD; Dodds, AJ; Ellis, T; Friedberg, JW; Ganjoo, KN; Herst, J; Joyce, R; LaCasce, AS; Lemieux, B; Leonard, JP; Martin, P; Montgomery, PG; Pressnail, B; Rajguru, SA; Robinson, KS; Smith, MR; Szer, J; van der Jagt, RH; VanderWalde, A; Williams, M | 1 |
| Castillo, JJ; Olszewski, AJ; Reagan, JL | 1 |
| Hiraga, J; Kagami, Y; Narita, M; Suzuki, N; Takagi, Y; Tomita, A | 1 |
| Inayat, F; Law, JK; Myers-Gurevitch, PM; Perlman, AS; Seshan, SV | 1 |
| Bahlo, J; Cramer, P; Eichhorst, B; Engelke, A; Fink, AM; Fischer, K; Hallek, M; Kovacs, G; Langerbeins, P; Maurer, C; Müller, L; Pflug, N; Ritgen, M; Seiler, T; Stilgenbauer, S; von Tresckow, J; Wendtner, CM | 1 |
| Chan, TS; Khong, PL; Kwong, YL | 1 |
1 trial(s) available for bendamustine hydrochloride and Cancer, Second Primary
| Article | Year |
|---|---|
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.
Topics: Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Case-Control Studies; Cell Transformation, Neoplastic; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Registries; Risk Assessment; Risk Factors; Vidarabine | 2016 |
8 other study(ies) available for bendamustine hydrochloride and Cancer, Second Primary
| Article | Year |
|---|---|
Risk of a second cancer and infection in patients with indolent B-cell lymphoma exposed to first-line bendamustine plus rituximab: A retrospective analysis of an administrative claims database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Case-Control Studies; Humans; Lymphoma, B-Cell; Neoplasms, Second Primary; Retrospective Studies; Rituximab | 2023 |
Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Datasets as Topic; Doxorubicin; Female; Humans; Lymphoma, B-Cell; Male; Medicare; Middle Aged; Neoplasms, Second Primary; Prednisone; Progression-Free Survival; Propensity Score; Registries; Rituximab; Treatment Outcome; United States; Vincristine | 2020 |
Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Chlorambucil; Cohort Studies; Denmark; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Registries; Risk Assessment; Survival Analysis; Vidarabine | 2021 |
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Disease-Free Survival; Female; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Rituximab; Time Factors; Treatment Outcome | 2017 |
Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Infections; Lymphoma, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine | 2018 |
Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
Topics: Antigens, CD20; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine | 2018 |
Minimal change disease: an unusual presentation of marginal zone MALT lymphoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Colonic Neoplasms; Diagnosis, Differential; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nephrosis, Lipoid; Proteinuria; Rituximab | 2016 |
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Vincristine | 2016 |